Alvotech touts 'critical inflection' but DeepValue report cautions on unresolved FDA risks

What happened

Alvotech's CSO declared a 'critical inflection period' as the biosimilar pipeline nears FDA decisions, highlighting limited-competition products and a broader launch cycle. The DeepValue master report, however, maintains a WAIT rating with a $3.75 attractive entry, citing the November 2025 AVT05 complete response letter that revealed recurring manufacturing deficiencies at the single Reykjavik facility. Despite the optimistic framing, the report emphasizes that the company still faces high secured leverage (~$1.1B debt), negative equity, and material weaknesses in internal controls. The market currently values Alvotech at ~17-20x 2025 adjusted EBITDA, which does not adequately compensate for concentrated regulatory, balance sheet, and execution risk. The news provides no new evidence that FDA remediation is complete or that cash flow generation has sustainably improved.

Implication

The current risk-reward remains unfavorable. Investors should require either a clear AVT05 remediation timeline and sustained positive cash flow, or a deeper share price decline toward $3.75, before upgrading the thesis.

Thesis delta

The news does not change the investment thesis. Management's optimistic inflection language is not backed by new operational data, and the DeepValue report's key risks—single-site FDA exposure, high leverage, and negative equity—remain unaddressed. The call remains WAIT, with no upgrade until FY2025 results show clear regulatory progress and free cash flow turns positive.